Sakra World Hospital, India’s first 100% FDI-funded tertiary care hospital, today launched its integrated and advanced Institute of Cancer Care and Blood Disorders, a dedicated centre aimed at delivering precision-driven, technology-enabled and patient-centric cancer and haematology care under one roof.
The newly launched institute brings together end-to-end oncology services, including medical oncology, surgical oncology, breast oncology, haematology, anaesthesiology, critical care, and advanced surgical specialties, supported by modern diagnostics and multidisciplinary tumour boards.
Dr Vineet Gupta, director & head – Institute of Cancer Care and Blood Disorders, Sakra World Hospital, said, “Advances in medical research and technology have significantly improved cancer outcomes, with many cancers today being highly treatable when detected early. In India, cancer incidence continues to rise, with over 14 lakh new cases reported every year, yet a large proportion of patients still present at advanced stages due to delayed diagnosis and low awareness. Timely detection, supported by education and access to quality care, can make a decisive difference.”
The institute will focus on organ-specific oncology, minimally invasive and robotic surgeries, chemotherapy, supportive and palliative care, and long-term survivorship programmes, ensuring continuity of care from diagnosis through recovery and beyond. Strong emphasis will also be placed on preventive oncology, patient education, and community awareness initiatives to promote early detection.
Yuichi Nagano, managing director, Sakra World Hospital, said, “The launch of the Institute of Cancer Care and Blood Disorders reinforces Sakra’s focus on combining Japanese precision, advanced medical technology, and clinical excellence to deliver globally benchmarked healthcare in India.”
Kei Iiyama, deputy managing director, Sakra World Hospital, said, “The institute aligns with Sakra’s strategy of building integrated, high-acuity centres that address the growing burden of complex diseases. By bringing multidisciplinary expertise, advanced technology, and streamlined care pathways together, we aim to improve clinical outcomes while enhancing efficiency and accessibility in cancer care delivery.”
Lovekesh Kumar Phasu, group chief operating officer, said, “With cancer cases rising steadily, there is a pressing need for integrated institutes that reduce treatment delays and improve coordination. This institute is designed to provide patients faster access to expert opinions, advanced therapies, and comprehensive support under one roof.” |